LAB Forecasts Revenue Between $80 Million and $85 Million for FY

robot
Abstract generation in progress

Standard BioTools Inc (LAB) has projected its fiscal year 2026 revenue to be between $80 million and $85 million. The company, which specializes in medical devices and instruments, operates with a strong balance sheet due to low debt-to-equity and strong liquidity, despite facing profitability challenges and being in a distress zone according to the Altman Z-Score. Valuation metrics show a complex scenario, with the stock approaching oversold territory and institutional ownership at 73.85%, complemented by recent insider buying.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)